Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers

Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers

UC San Diego study indicates mutant HRAS is a key, cancer-driving oncogene — and that it’s a druggable target

July 30, 2020  |  Scott LaFee